Semaglutide denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Semaglutide as Duplicate Therapy

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and, in higher-dose formulations, for chronic weight management. A duplicate-therapy denial from Aetna typically occurs when the member is already dispensed another GLP-1 receptor agonist (such as a different branded or generic agent in the same class), or when Aetna's system interprets an overlapping claim as a therapeutically redundant prescription. This is frequently an administrative or clinical-documentation issue rather than a true clinical dispute.

## Why This Denial Is Appealable

Duplicate-therapy edits are designed to catch genuine redundancy — two drugs from the same class serving the same purpose simultaneously. They are not designed to block a prescriber from switching a patient to a different agent within a class, or from using semaglutide for a distinct indication (for example, weight management when the other agent was prescribed only for glycemic control). If the clinical picture supports the prescription, this denial can be overturned.

## Your Federal Appeal Rights

• Internal appeal: File immediately, with a prescriber letter explaining the clinical reason for semaglutide specifically and how it differs from or replaces the alleged duplicate.
• ACA §2719 / External Review: After an adverse internal decision, independent external review is available. You generally have approximately four months from the denial notice to request it.
• ERISA §503 (employer plans): Entitles you to the complete claim file, the therapeutic-duplication policy applied, and a full-and-fair review.
• Expedited review: Available if delay poses a risk to your health.

## Appeal Timeline

1. Determine which drug Aetna identified as the duplicate — request this in writing. 2. Have your prescriber clarify the clinical rationale: is this a switch (prior drug discontinued), a distinct indication, or a clinically justified combination? 3. File the internal appeal with a prescriber letter and prescription/dispensing history showing the prior drug is discontinued or serves a different purpose. 4. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• Prescription history: Pharmacy dispensing records showing the status (active vs. discontinued) of any other GLP-1 or diabetes/weight-management agent.
• Prescriber clarification letter: A letter specifying that semaglutide is replacing the prior agent, or that it is prescribed for a distinct indication not covered by the other drug.
• Diagnosis documentation: Chart notes confirming the indication(s) for which semaglutide is prescribed.
• Discontinuation records: If the alleged duplicate has been stopped, documentation of the stop date and reason.

## Criteria-Mapping Structure

Obtain Aetna's therapeutic-duplication policy. For each element of the duplication criteria, document the specific chart fact that refutes duplication — for example, a discontinuation date or a distinct diagnosis. Present this as a side-by-side table so the reviewer can see at a glance that the duplication rationale does not hold for this patient.